XML 23 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenues
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenues REVENUES
Disaggregation of Revenues
Revenues were as follows:
Year Ended December 31, 2021Year Ended December 31, 2020Year Ended December 31, 2019
(in millions)U.S.EuropeOther InternationalTotalU.S.EuropeOther InternationalTotalU.S.EuropeOther InternationalTotal
Product Sales:
HIV
Atripla$121 $12 $12 $145 $307 $21 $21 $349 $501 $60 $39 $600 
Biktarvy7,049 969 606 8,624 6,095 735 429 7,259 4,225 370 143 4,738 
Complera/Eviplera102 142 14 258 89 159 21 269 160 214 32 406 
Descovy1,397 164 139 1,700 1,526 197 138 1,861 1,078 255 167 1,500 
Genvoya2,267 391 221 2,879 2,605 490 243 3,338 2,984 664 283 3,931 
Odefsey1,076 440 52 1,568 1,172 450 50 1,672 1,180 438 37 1,655 
Stribild132 43 14 189 125 54 17 196 268 75 26 369 
Truvada314 22 35 371 1,376 27 45 1,448 2,640 101 72 2,813 
Revenue share - Symtuza(1)
355 165 11 531 331 149 8 488 249 130 — 379 
Other HIV(2)
15 18 17 50 25 5 28 58 30 5 12 47 
Total HIV 12,828 2,366 1,121 16,315 13,651 2,287 1,000 16,938 13,315 2,312 811 16,438 
Veklury3,640 1,095 830 5,565 2,026 607 178 2,811 — — — — 
Hepatitis C virus (“HCV”)
Ledipasvir/
Sofosbuvir(3)
84 31 97 212 92 29 151 272 312 71 260 643 
Sofosbuvir/Velpatasvir(4)
815 316 331 1,462 864 337 398 1,599 971 553 441 1,965 
Other HCV(5)
119 74 14 207 132 48 13 193 182 118 28 328 
Total HCV1,018 421 442 1,881 1,088 414 562 2,064 1,465 742 729 2,936 
Hepatitis B virus (“HBV”) / Hepatitis Delta virus (“HDV”)
Vemlidy384 34 396 814 356 29 272 657 309 21 158 488 
Viread11 28 72 111 14 34 137 185 32 69 142 243 
Other HBV/HDV(6)
2 42 — 44 10 8 — 18 2 9 — 11 
Total HBV/HDV397 104 468 969 380 71 409 860 343 99 300 742 
Cell Therapy
Tecartus136 40 — 176 34 10 — 44 — — — — 
Yescarta406 253 36 695 362 191 10 563 373 83 — 456 
Total Cell Therapy 542 293 36 871 396 201 10 607 373 83 — 456 
Trodelvy370 10 — 380 49 — — 49 — — — — 
Other
AmBisome39 274 227 540 61 230 145 436 37 234 136 407 
Letairis206 — — 206 314 — — 314 618 — — 618 
Ranexa10 — — 10 9 — — 9 216 — — 216 
Zydelig26 35 1 62 31 39 2 72 47 54 2 103 
Other(7)
100 80 29 209 136 45 14 195 151 43 9 203 
Total Other 381 389 257 1,027 551 314 161 1,026 1,069 331 147 1,547 
Total product sales19,176 4,678 3,154 27,008 18,141 3,894 2,320 24,355 16,565 3,567 1,987 22,119 
Royalty, contract and other revenues91 196 10 297 76 241 17 334 80 244 6 330 
Total revenues$19,267 $4,874 $3,164 $27,305 $18,217 $4,135 $2,337 $24,689 $16,645 $3,811 $1,993 $22,449 
_______________________________
(1)     Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”).
(2)     Includes Emtriva and Tybost.
(3)     Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.
(4)     Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.
(5)     Includes Vosevi and Sovaldi.
(6)     Includes Hepcludex and Hepsera.
(7)     Includes Cayston and Jyseleca.
Revenues From Major Customers
The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:
Year Ended December 31,
(as a percentage of total revenues)202120202019
AmerisourceBergen Corporation23 %27 %21 %
Cardinal Health, Inc.22 %21 %21 %
McKesson Corporation20 %20 %22 %
Revenues Recognized from Performance Obligations Satisfied in Prior Periods
Revenues recognized from performance obligations satisfied in prior years related to our revenue share with Janssen, as described in Note 11. Collaborations and Other Arrangements, and royalties for licenses of our intellectual property were $851 million, $841 million and $741 million for the years ended December 31, 2021, 2020 and 2019, respectively.
Revenues from product sales, net of gross-to-net deductions, are recorded only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with gross-to-net deductions is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates related to sales made in prior years resulted in $856 million, $101 million and $257 million increase in revenues for the years ended December 31, 2021, 2020 and 2019, respectively. This was primarily related to changes in estimates for accrued government and other rebates and allowances for sales returns upon product expiration.
Contract Balances
Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $174 million and $198 million as of December 31, 2021 and 2020, respectively. Contract liabilities, which generally result from receipt of advance payment before our performance under the contract, were not material as of December 31, 2021 and 2020, respectively. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.